Acceleron Pharma Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Habib Dable
- Full Time Employees
- 312
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 128 Sidney St Cambridge MA United States of America 02139
- IPO Date
- Sep 18, 2013
- CIK
- 0001280600
- Website
- acceleronpharma.com
- Similar Companies
- Business
- Acceleron Pharma Inc. (XLRN) is a biopharmaceutical company focused on the discovery, development, and commercialization of transformative medicines targeting rare pulmonary diseases, particularly pulmonary arterial hypertension (PAH) and pulmonary hypertension due to left heart disease (PH-LHD). The company offers a pipeline of product candidates including sotatercept, a first-in-class activin signaling inhibitor designed to restore balanced activin signaling in the diseased pulmonary endothelium to address the underlying pathophysiology of PAH; and imbetelstat (formerly MK-6332), a telomerase inhibitor for the treatment of essential thrombocythemia; as well as earlier-stage candidates like REBLOZYL (luspatercept-aamt), a first-in-class erythroid maturation agent for the treatment of anemia in patients with beta-thalassemia and myelodysplastic syndromes. Founded in 2003 and headquartered in Cambridge, Massachusetts, Acceleron operates primarily in the United States with a focus on biotech research and clinical development targeting specialized patient populations in rare cardiopulmonary disorders. In November 2021, Acceleron was acquired by Merck & Co., Inc. (known as MSD outside the United States and Canada) for approximately $11.5 billion in an all-cash transaction, marking a significant strategic shift as its lead asset sotatercept was integrated into Merck's pipeline and received accelerated FDA approval in March 2024 under the brand name WINREVAIR for the treatment of adults with PAH (WHO Group 1) to increase exercise capacity, improve WHO functional class, and reduce clinical worsening; this acquisition represented Acceleron's most pivotal recent change, with no major independent developments thereafter as it ceased standalone operations.
Merck Scores A 'Must-Win' For Its $11.5 Billion Acceleron Buyout
Avoro Capital Urges Acceleron Shareholders Not to Tender Into Merck's Inadequate Offer
Is Merck's Planned Acquisition of Acceleron in Trouble?
Avoro Capital Releases Presentation Detailing Why Acceleron Shareholders Should Not Tender Into Merck's Inadequate Offer
Acceleron Pharma (XLRN) Reports Q3 Loss, Lags Revenue Estimates
Acceleron Reports Third Quarter 2021 Financial Results
SHAREHOLDER ALERT: WeissLaw LLP Reminds DWSN, PAE, XLRN, and FLXN Shareholders About Its Ongoing Investigations
Merck Pushes Acceleron Buyout By Refiling For Antitrust Review
Avoro Capital Issues Open Letter to Fellow Acceleron Pharma Shareholders
Acceleron Announces Third Quarter 2021 REBLOZYL® Net Sales
SHAREHOLDER ALERT: WeissLaw LLP Reminds MDP, GWB, XLRN and HFC Shareholders About Its Ongoing Investigations
Bristol Myers Pledges To Offload Acceleron Shares: Bloomberg
Darwin Global Urges Acceleron Shareholders Not to Tender Their Shares to Merck
ACCELERON PHARMA ALERT: Investors Should Contact Bragar Eagel & Squire, P.C. Over Tender Offer for XLRN Shares
SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Acceleron Pharma Inc. - XLRN
Holocene Advisors says Merck's offer undervalues Acceleron
Holocene Advisors Believes Merck's Proposed Offer of $180 Per Share for Acceleron Significantly Undervalues Company
Is an Acquisition of Acceleron a Smart Move for Merck?
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation into the Fairness of the Merger of Acceleron Pharma Inc. with Merck & Co., Inc.
With Acceleron Acquisition Merck Stock Is Likely To See A Multiple Revision